Showing results (161-170 of 242) with videos related to

Sort By:
Pageof 25
Blood|November 8, 2003
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignanciesJean-Pierre J Issa, Guillermo Garcia-Manero, Francis J Giles, et al.
Plos One|August 23, 2011
Mechanisms of resistance to decitabine in the myelodysplastic syndromeTaichun Qin, Ryan Castoro, Samih El Ahdab, et al.
Epigenetics|March 8, 2012
Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemiaJumpei Yamazaki, Rodolphe Taby, Aparna Vasanthakumar, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Rationally designed inhibitors of the Musashi protein-RNA interaction by hotspot mimicryNan Bai, Yusuf Adeshina, Igor Bychkov, et al.
The American Journal of Pathology|March 29, 2005
BRAF mutations in aberrant crypt foci and hyperplastic polyposisRobyn Beach, Annie On-On Chan, Tsung-Teh Wu, et al.
Blood|June 5, 2008
Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapseHeike Kroeger, Jaroslav Jelinek, Marcos R H Estécio, et al.
Annals of Hematology|July 13, 2006
PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoterYoko Tabe, Marina Konopleva, Yutaka Kondo, et al.
Epigenetics|December 20, 2012
The epigenome of AML stem and progenitor cellsJumpei Yamazaki, Marcos R Estecio, Yue Lu, et al.
EMBO Reports|February 19, 2011
Histone deacetylase inhibitor activity in royal jelly might facilitate caste switching in beesAstrid Spannhoff, Yong Kee Kim, Noel J-M Raynal, et al.
Plos One|July 16, 2011
Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemiaJaroslav Jelinek, Vazganush Gharibyan, Marcos R H Estecio, et al.
Pageof 25